Anna Nijdam
Known title: Principal Accounting OfficerCIK: 0001973872
Associated companies
Transaction History
| PHVS | ▼ Sell | Open Market | 2,670 | $82K | 6/4/2026 | View on chart |
| PHVS | ▲ Buy | Option Exercise | 5,501 | $110K | 5/22/2026 | View on chart |
| PHVS | ▼ Sell | Open Market | 5,501 | $169K | 5/22/2026 | View on chart |
| PHVS | ▲ Buy | Option Exercise | 1,829 | $37K | 5/21/2026 | View on chart |
| PHVS | ▼ Sell | Open Market | 1,829 | $56K | 5/21/2026 | View on chart |
| PHVS | ▼ Sell | Tax Withholding | 548 | $15K | 4/11/2026 | View on chart |
| PHVS | ▼ Sell | Tax Withholding | 1,167 | $33K | 4/6/2026 | View on chart |
| PHVS | ▼ Sell | Tax Withholding | 1,164 | $33K | 4/1/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Pharvaris publishes Phase 3 deucrictibant data in The Lancet
Pharvaris reported Phase 3 results for deucrictibant IR in The Lancet, showing symptom relief in 1.28 hours and complete resolution in 11.95 hours for HAE attacks. The company stated that the New Drug Application and Marketing Authorization Application are currently under review. Additional real-world data on patient preferences was also published, providing context for the treatment strategy.
Pharvaris publishes Phase 3 deucrictibant data in The Lancet. Pharvaris reported Phase 3 results for deucrictibant IR in The Lancet, showing symptom relief in 1.28 hours and complete resolution in 11.95 hours for HAE attacks. The company stated that the New Drug Application and Marketing Authorization Application are currently under review. Additional real-world data on patient preferences was also published, providing context for the treatment strategy.